These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20571535)

  • 21. Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists.
    López JM; Oestreicher E
    Fertil Steril; 2005 Sep; 84(3):756. PubMed ID: 16169415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.
    Pereira AM
    Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

  • 24. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
    Ioachimescu AG; Fleseriu M; Hoffman AR; Vaughan Iii TB; Katznelson L
    Eur J Endocrinol; 2019 Jan; 180(1):31-40. PubMed ID: 30400048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine agonist therapy for hyperprolactinemia.
    Bankowski BJ; Zacur HA
    Clin Obstet Gynecol; 2003 Jun; 46(2):349-62. PubMed ID: 12808385
    [No Abstract]   [Full Text] [Related]  

  • 26. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia.
    Kilicdag EB; Tarim E; Bagis T; Erkanli S; Aslan E; Ozsahin K; Kuscu E
    Int J Gynaecol Obstet; 2004 Jun; 85(3):292-3. PubMed ID: 15145274
    [No Abstract]   [Full Text] [Related]  

  • 27. Cabergoline and mitral regurgitation.
    Delgrange E
    N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779
    [No Abstract]   [Full Text] [Related]  

  • 28. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
    Miki N
    Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
    [No Abstract]   [Full Text] [Related]  

  • 29. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia.
    Kars M; Souverein PC; Herings RM; Romijn JA; Vandenbroucke JP; de Boer A; Dekkers OM
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2729-34. PubMed ID: 19491225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
    Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
    Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine agonist therapy and cardiac valve dysfunction.
    Sherlock M; Steeds R; Toogood AA
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):643-4. PubMed ID: 17645575
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
    Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
    Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indications for hyperprolactinemia therapy.
    Olive D
    J Reprod Med; 1999 Dec; 44(12 Suppl):1091-4. PubMed ID: 10649816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of hyperprolactinemia in infertility.
    Crosignani PG
    J Reprod Med; 1999 Dec; 44(12 Suppl):1116-20. PubMed ID: 10649821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia.
    Gómez R; Abad A; Delgado F; Tamarit S; Simón C; Pellicer A
    Fertil Steril; 2011 Mar; 95(3):882-8.e1. PubMed ID: 21055747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.
    Dekkers OM; Lagro J; Burman P; Jørgensen JO; Romijn JA; Pereira AM
    J Clin Endocrinol Metab; 2010 Jan; 95(1):43-51. PubMed ID: 19880787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G; Fuhrmann JT; Strasser RH
    Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idiopathic granulomatous mastitis associated with hyperprolactinemia: A nonoperative approach.
    Li J; McGregor HP
    Breast J; 2017 Nov; 23(6):742-744. PubMed ID: 28845595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report.
    Sato H; Asami Y; Shiro R; Yasuda M; Imai S; Sakai R; Oida K; Kawaharamura K; Taguchi N; Suzuki T; Hirose M
    Gynecol Endocrinol; 2018 Mar; 34(3):199-201. PubMed ID: 28925774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.